Delivers margin expansion, strong cash generation, and establishes fiscal year 2026 guidance

Maximus (NYSE: MMS), a leading provider of government services, reported financial results for the three months and year ended September 30, 2025.

Highlights for fiscal year 2025 include:

• Full year revenue increased 2.4% to $5.43 billion, compared to $5.31 billion for the prior year. Organic growth was 3.9% and driven by high demand for clinical services within the U.S. Federal Services Segment.
• Full year operating margin was 9.7% and the adjusted EBITDA margin was 12.9%, reflecting year-over-year margin expansion. Full year diluted earnings per share were $5.51, and adjusted diluted earnings per share were $7.36.
• Full year cash flows from operating activities totaled $429 million, and free cash flow was $366 million. Purchases of Maximus common stock totaled 5.8 million shares for $457 million during the full year. The leverage ratio at September 30, 2025, was 1.5x, as calculated in accordance with our credit agreement.
• A quarterly cash dividend of $0.30 per share payable on December 1, 2025, to shareholders of record on November 14, 2025.

"Fiscal 2025 was a year of significant achievement for Maximus, as our teams skillfully navigated shifting priorities, seized opportunities to step up for our customers, and ultimately delivered revenue growth and profitability well above our expectations at the beginning of the fiscal year," said Bruce Caswell, President and Chief Executive Officer. "Our performance underscores the essential nature of the services we provide, and the trust customers place in us to deliver meaningful outcomes."

Caswell continued, "For fiscal 2026, Maximus is prioritizing expansion in U.S. Federal markets, preparing for opportunities from recent Federal legislation, and deploying AI‑enabled automation designed to drive productivity and operating leverage that we believe will enable growth acceleration in 2027 and beyond."

Consolidated Fiscal Year 2025 Results

Revenue for the full fiscal year 2025 increased 2.4% to $5.43 billion, compared to $5.31 billion for the prior year. Organic growth was 3.9% over the prior year due primarily to volume growth on clinical programs in the U.S. Federal Services Segment.

For the full fiscal year 2025, the operating margin was 9.7% and adjusted EBITDA margin was 12.9%. This compares to margins of 9.2% and 11.6%, respectively, for the prior fiscal year. Higher volumes in the U.S. Federal Services Segment, combined with technology and cost initiatives, drove the year-over-year improvement and demonstrate the benefits of our strategic focus on clinical programs and tech-enabled service delivery.

Diluted earnings per share were $5.51 and adjusted diluted earnings per share were $7.36. This compares to $4.99 and $6.11, respectively, for the prior year. The majority of the earnings improvement was attributable to enhanced operating profitability, with a smaller contribution derived from the purchase of Maximus common stock.

U.S. Federal Services Segment

U.S. Federal Services Segment revenue for fiscal year 2025 increased 12.1% to $3.07 billion, compared to $2.74 billion reported for the prior year. All growth was organic and driven predominantly by a combination of anticipated and unforeseen volume growth across a range of clinical programs, further reinforcing U.S. Federal Services as a strong growth engine. In addition, natural disaster support activities provided a greater contribution to fiscal year 2025 as compared to the prior year.

The segment operating margin for the full fiscal year 2025 was 15.3%, as compared to 12.2% reported for the prior fiscal year. The margin improvement was attributable to clinical program-related volume growth improving the operating leverage of the segment, along with productivity enhancements tied to technology initiatives.

U.S. Services Segment

U.S. Services Segment revenue for fiscal year 2025 decreased by 7.7% to $1.76 billion, compared to $1.91 billion reported in the prior fiscal year. The decrease was primarily due to the prior fiscal year period containing excess volumes from Medicaid-related activities, including the extra redeterminations from the unwinding exercise.

The segment operating margin for fiscal year 2025 was 9.7%, compared to 12.9% reported in the prior fiscal year. The higher margin in the prior year period was a direct benefit of the excess volumes that were temporary. In addition, the segment's operating income was impacted by a meaningful portion of the company's $16 million of severance charges booked in the fourth quarter of fiscal year 2025.

Outside the U.S. Segment

Outside the U.S. Segment revenue for fiscal year 2025 decreased 8.7% to $599.9 million as compared to $657.1 million reported for the prior fiscal year. The revenue reduction was due to the divestitures of multiple employment services businesses, and was partially offset by positive organic growth of 4.1%.

The segment operating margin for fiscal year 2025 was 3.7%, compared to 1.2% reported in the prior fiscal year. The segment is operating within its 3% to 7% target margin range due to divesting more volatile elements of the portfolio. Our goal remains to move the segment higher in the target margin range in future periods.

Sales and Pipeline

Year-to-date signed contract awards at September 30, 2025, totaled $4.7 billion, and contracts pending (awarded but unsigned) totaled $331 million. The book-to-bill ratio at September 30, 2025, was 0.9x on a trailing twelve-month basis.

The total sales pipeline at September 30, 2025, was $51.3 billion (comprised of approximately $3.37 billion in proposals pending, $1.37 billion in proposals in preparation, and $46.6 billion in opportunities tracking). New work opportunities represent approximately 64% of the total sales pipeline, and U.S. Federal Services Segment opportunities represent approximately 66% of the total sales pipeline, providing a diversified set of future growth drivers with an increasing tilt toward U.S. Federal programs.

Balance Sheet and Cash Flows

At September 30, 2025, cash and cash equivalents totaled $222 million, and gross debt was $1.35 billion. The ratio of debt, net of allowed cash, to consolidated EBITDA for the full year ended September 30, 2025, as calculated in accordance with our credit agreement, was 1.5x, as compared to 2.1x at June 30, 2025, providing meaningful financial flexibility for continued investment and shareholder returns.

For fiscal year 2025, cash flows from operating activities totaled $429 million and free cash flow was $366 million, enabled by $642 million of free cash flow for the quarter ended September 30, 2025. This compares to $515 million and $401 million, respectively, in the prior fiscal year. DSO at September 30, 2025, were 62 days, demonstrating strong improvement of collections as expected following the 96-day DSO for the period ended June 30, 2025.

During fiscal year 2025, we purchased approximately 5.8 million shares of Maximus common stock totaling $456.6 million. Subsequent to September 30, 2025, we purchased approximately 0.4 million shares totaling $30.7 million. Including the subsequent activity, approximately $250 million remains on the current $400 million Board of Directors authorization granted in September 2025.

On October 6, 2025, our Board of Directors declared a quarterly cash dividend of $0.30 for each share of our common stock outstanding. The dividend is payable on December 1, 2025, to shareholders of record on November 14, 2025.

Fiscal Year 2026 Outlook

Maximus is establishing fiscal year 2026 guidance. We expect revenue to range between $5.225 billion and $5.425 billion. We anticipate an adjusted EBITDA margin of approximately 13.7% for the full fiscal year. We expect adjusted diluted earnings per share, which excludes expense for amortization of intangible assets and divestiture-related charges, to range between $7.95 and $8.25 per share.

We expect free cash flow to range between $450 million and $500 million for fiscal year 2026. We forecast expenses of $81 million for amortization of intangible assets, $58 million for depreciation and amortization, and $69 million for interest is anticipated for the full fiscal year. We expect an effective income tax rate of approximately 25% and weighted average shares outstanding of about 55.5 million is expected for fiscal year 2026.

Conference Call and Webcast Information

Maximus will host a conference call today, November 20, 2025, at 9:00 a.m. ET.

The call is open to the public and available by webcast or by phone at:

877.407.8289 (Domestic) / +1.201.689.8341 (International)

For those unable to listen to the live call, a recording of the webcast will be available on investor.maximus.com.

About Maximus

As a leading strategic partner to government, Maximus helps improve the delivery of public services amid complex technology, health, economic, and social challenges. With a deep understanding of program service delivery, acute insights that achieve operational excellence, and an extensive awareness of the needs of the people being served, our employees advance the critical missions of our partners. Maximus provides tech-enabled services to government agencies, including innovative business process management and technology solutions, that provide improved outcomes for the public and higher levels of productivity and efficiency of government-sponsored programs. For more information, visit maximus.com.

Non-GAAP Measures and Risk Factors

This release contains non-GAAP measures and other indicators, including organic growth, free cash flow, EPS adjusted for amortization of intangible assets and divestiture-related charges, adjusted EBITDA, consolidated EBITDA (as defined by our Credit Agreement) and other non-GAAP measures.

A description of these non-GAAP measures and details as to how they are calculated are included with our earnings presentation and forthcoming Form 10-K.

The presentation of these non-GAAP numbers is not meant to be considered in isolation, nor as alternatives to cash flows from operations, revenue growth, operating income, or net income as measures of performance. These non-GAAP financial measures, as determined and presented by us, may not be comparable to related or similarly titled measures presented by other companies.

Statements that are not historical facts, including statements about our confidence and strategies, and our guidance and expectations about revenues, results of operations, profitability, future contracts, market opportunities, market demand, or acceptance of our products are forward-looking statements that involve risks and uncertainties.

These risks could cause our actual results to differ materially from those indicated by such forward-looking statements. The guidance is only effective as of the date given. We undertake no obligation to update the guidance herein as circumstances evolve. A summary of risk factors can be found in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed on November 21, 2024, as supplemented by the risk factor set forth in Part II, Item 1A "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which was filed with the SEC on May 8, 2025. Our Securities and Exchange Commission (SEC) reports are accessible on maximus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251120109408/en/